NDM-35-Producing ST167 Escherichia coli Highly Resistant to β-Lactams Including Cefiderocol

Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0031122. doi: 10.1128/aac.00311-22. Epub 2022 Jul 11.

Abstract

A multidrug-resistant (carbapenems, aztreonam + avibactam, and cefiderocol) ST167 Escherichia coli clinical isolate recovered from a patient hospitalized in Switzerland produced NDM-35 showing ca. 10-fold increased hydrolytic activity toward cefiderocol compared to NDM-1. The isolate co-produced a CMY-type β-lactamase, exhibited a four amino-acid insertion in PBP3, and possessed a truncated iron transporter CirA protein. Our study identified an association of unrelated resistance mechanisms leading to resistance to virtually all β-lactams in a high-risk E. coli clone.

Keywords: NDM; aztreonam-avibactam; cefiderocol; metallo-β-lactamase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Cefiderocol
  • Cephalosporins
  • Drug Resistance, Multiple, Bacterial / genetics
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli* / genetics
  • Escherichia coli* / metabolism
  • Humans
  • Microbial Sensitivity Tests
  • beta-Lactamases / genetics
  • beta-Lactamases / metabolism
  • beta-Lactams / pharmacology

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • beta-Lactams
  • beta-Lactamases